Shares of DexCom (NASDAQ:DXCM) on Thursday surged more than 14% in extended trading, after the medical device maker raised its full year revenue guidance and announced a new $500M share buyback. DXCM ...
DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock. DexCom makes continuous glucose monitoring (CGM) devices, which are crucial for ...
Medical device company DexCom (NASDAQ:DXCM) announced in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus Estimate of 57 cents by 7%. The company reported earnings of 45 cents per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback